| Name | Dalafeni+Trimetini |
| Use | Darafenib and trametinib have previously been approved in China for the treatment of BRAF V600 mutation-positive melanoma and have entered the health insurance list. In clinical trials, the 5-year overall survival rates of dalafenib plus trametinib in patients with treated and untreated lung cancer were 19% and 22%, respectively. This further validates the efficacy of dalafenib combined with trametinib for advanced non-small cell lung cancer with BRAF V600 mutation. |